Key Takeaways & Executive Findings
- •• Non-aqueous electrolytes are pivotal for lithium-ion battery performance, safety, and longevity. • Recent advances in lithium salts, solvents, and additives enable high-voltage and wide-temperature operation. • Interfacial engineering and electrolyte formulation are key to mitigating degradation and improving cycle life. • Future electrolyte designs must balance ionic conductivity, electrochemical stability, and safety for next-generation batteries.
Abstract
Non-aqueous electrolytes are critical components of lithium-ion batteries, directly influencing their performance, safety, and lifespan. This review systematically summarizes the composition, functional mechanisms, and recent advances in non-aqueous electrolytes, including lithium salts, solvents, and additives. Key challenges such as interfacial stability, high-voltage operation, and low-temperature performance are addressed. The paper also discusses emerging strategies for designing advanced electrolytes to meet the demands of next-generation high-energy-density batteries. The insights provided aim to guide future research and industrial applications in the field of electrochemical energy storage.
1. Introduction
Lithium-ion batteries (LIBs) have become the dominant power source for portable electronics, electric vehicles, and grid storage due to their high energy density and long cycle life. The electrolyte, though often overlooked, plays a crucial role in determining the overall performance and safety of LIBs. Non-aqueous electrolytes, typically composed of lithium salts dissolved in organic solvents with functional additives, facilitate ion transport between electrodes and form the solid electrolyte interphase (SEI) that governs interfacial stability.
Despite significant progress, challenges remain in developing electrolytes that can operate under extreme conditions, such as high voltages, low temperatures, and fast charging. The decomposition of conventional carbonate solvents at high potentials and the formation of unstable SEI layers lead to capacity fading and safety hazards. Therefore, understanding the fundamental chemistry of non-aqueous electrolytes and exploring novel materials are essential for advancing LIB technology.
This review provides a comprehensive overview of non-aqueous electrolytes, covering their components, design principles, and recent innovations. We highlight the relationships between electrolyte structure and performance, and discuss future directions for developing high-performance electrolytes for next-generation batteries.
Loading authentic research manuscript (Pages 1–5)...
Jianmin Ma, Yan Wang, ... (2026). Core Technology and Applications of Non-Aqueous Electrolyte for Lithium-Ion Batteries. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_40
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is a non-aqueous electrolyte in lithium-ion batteries?
A non-aqueous electrolyte is a solution of lithium salts in organic solvents, used in lithium-ion batteries to facilitate ion transport between the anode and cathode. It is essential for battery operation and performance.
Why are non-aqueous electrolytes important for battery performance?
Non-aqueous electrolytes determine the ionic conductivity, electrochemical stability, and interfacial properties of the battery, directly affecting its capacity, cycle life, and safety.
What are the main components of a non-aqueous electrolyte?
The main components are lithium salts (e.g., LiPF6), organic solvents (e.g., ethylene carbonate, dimethyl carbonate), and functional additives that improve SEI formation, flame retardancy, and other properties.
What challenges exist in developing non-aqueous electrolytes?
Challenges include achieving high voltage stability, low-temperature performance, and safety, as well as mitigating electrolyte decomposition and interfacial degradation.
How can advanced electrolytes improve next-generation batteries?
Advanced electrolytes with optimized compositions and novel additives can enable higher energy densities, longer cycle life, and safer operation, supporting the development of next-generation batteries.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.